絞り込み

16639

広告

里山のチョウ類が激減 耕作放棄地増加などが影響か 環境省 (NHK)

里山などに生息するチョウ類のうち、ミヤマカラスアゲハなど34種の数が急速に減少していることが環境省などの調査でわかりました。 環境省と日本自然保護協会は大学や住...

  1. [医学] 異常をきたすと癌を生じやすくす...
  2. 松本零士さん快方へ 病院側「意識戻った」...
  3. 第160回 夜中に台所でバナナをかじった...
  4. 古代エジプトに大量の鳥ミイラの謎、異説が...

ニュース一覧

Immunotherapy in myeloma: how far have we come?

著者 Franssen LE , Mutis T , Lokhorst HM , van de Donk NWCJ
Ther Adv Hematol.2019 ; 10():2040620718822660.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (548view , 0users)

Full Text Sources

Miscellaneous

The treatment of multiple myeloma (MM) has evolved substantially over the past decades, leading to a significantly improved outcome of MM patients. The introduction of high-dose therapy, especially, and autologous stem cell transplantation, as well as the development of new drugs, such as immunomodulatory drugs (IMiDs) and proteasome inhibitors have contributed to the improvement in survival. However, eventually most MM patients relapse, which indicates that there is a need for new agents and novel treatment strategies. Importantly, the long-term survival in a subset of MM patients after allogeneic stem cell transplantation illustrates the potential of immunotherapy in MM, but allogeneic stem cell transplantation is also associated with a high rate of treatment-related mortality. Recently, a better insight into several immune-evasion mechanisms, which contribute to tumor progression, has resulted in the development of active and well-tolerated novel forms of immunotherapy. These immunotherapeutic agents can be used as monotherapy, or, even more successfully, in combination with other established anti-MM agents to further improve depth and duration of response by preventing the outgrowth of resistant clones. This review will discuss the mechanisms used by MM cells to evade the immune system, and also provide an overview of currently approved immunotherapeutic drugs, such as IMiDs (e.g. lenalidomide and pomalidomide) and monoclonal antibodies that target cell surface antigens present on the MM cell (e.g. elotuzumab and daratumumab), as well as novel immunotherapies (e.g. chimeric antigen receptor T-cells, bispecific antibodies and checkpoint inhibitors) currently in clinical development in MM.
PMID: 30719268 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード